Popular Articles

Seattle Genetics Initiates Brentuximab Vedotin (SGN-35) Retreatment Clinical Trial
Seattle Genetics, Inc. (Nasdaq: SGEN) announced that it has initiated a phase II clinical trial of brentuximab vedotin (SGN-35), an antibody-drug conjugate (ADC), for the retreatment of patients with Hodgkin lymphoma and systemic anaplastic large cell lymphoma (ALCL). This trial is designed to evaluate tolerability and activity when retreating patients who relapse after previously achieving an objective response to brentuximab vedotin.
generic viagra online
First International Conference On Cancer Of Unknown Primary To Be Held London October 15
When a patient is diagnosed with metastatic disease the primary site of the cancer is usually, but not always, evident. When the origin of the cancer is not identified it is described as a Cancer of Unknown Primary site, or CUP.
News of the day
Autonomous Robot Detects Shrapnel
Bioengineers at Duke University have developed a laboratory robot that can successfully locate tiny pieces of metal within flesh and guide a needle to its exact location -- all without the need for human assistance.
Mental Health

National All Schedules Prescription Electronic Reporting (NASPER) Act Receives Senate Support

The American Society of Interventional Pain Physicians (ASIPP) announced that the National All Schedules Prescription Electronic Reporting (NASPER) Act has received the support of Senator John D. Rockefeller IV of West Virginia and Senator Bob Corker of Tennessee. NASPER was unanimously passed by both the House and the Senate and signed into law on August 11, 2005 by President George W. Bush, and received preliminary funding of $2 million for the Fiscal Year 2009 and 2010. Proposed by ASIPP, with the support of the American Medical Association, the American Society of Anesthesiologists and other organizations, NASPER"s purpose is to provide and improve patient access to quality care. It was also created to protect patients and physicians from the deleterious effects of controlled substance misuse, abuse and trafficking. The ultimate goal of NASPER is to have a coordinated prescription monitoring program in all 50 states, which could save hundreds of millions of dollars in prescriptions in the Medicaid and Medicare programs. "While the preliminary funding of NASPER is a promising start, it is imperative to secure full funding in order to realize its full potential and possibly save countless numbers of lives," said Dr. Laxmaiah Manchikanti, ASIPP CEO and Chairman of the Board. "The abuse of prescription drugs continues to be a problem that plagues millions of Americans and their families every day," said Rep. Ed Whitfield who first authored the legislation in the 108th Congress. "NASPER is a powerful weapon in the fight against prescription drug abuse that will allow physicians to detect abuse and prevent the practice of doctor shopping across state lines. I am pleased that NASPER has, at long last, received the funding that it needs to be implemented and start saving lives." According to the National Institute of Drug Abuse, abuse of prescription medications is on the rise. Prescription drug monitoring programs are an important tool to help and track illegal activity related to the prescription of these drugs. Senators Rockefeller and Corker have stated that NASPER is a "vital tool for states to combat substance abuse," and urge the Appropriations Committee to provide $25 million for the 2010 Fiscal Year. Currently, there are 38 states that individually fund their own prescription monitoring programs based on requirements originally set by NASPER. With additional appropriated support, states will have the res necessary to enhance their programs and meet statutorily defined requirements. "NASPER has made strides since its inception in 2005, but the endorsement of Senator Rockefeller and Senator Corker will hopefully move NASPER into the next crucial phase," said Dr. Manchikanti. "We are so grateful for the support from the senators and those who have shown dedication over the years, especially the tireless efforts of Rep. Ed Whitfield, Rep. Bart Stupak, Sen. Jeff Sessions, and Sen. Richard Durbin." About The American Society of Interventional Pain Physicians ASIPP"s mission statement is to promote the development and practice of safe, high quality, cost-effective interventional pain management techniques for the diagnosis and treatment of pain and related disorders, and to ensure patient access to these interventions. Founded in 1998 by current CEO Laxmaiah Manchikanti, MD, ASIPP is a rapidly growing not-for-profit organization that supports the needs of physicians who practice Interventional Pain Management across the country. Since its inception, the organization has had substantial impact on the practice of interventional pain medicine, resulting in an impressive list of major achievements. In 2005, ASIPP succeeded in passing The National All Schedules Prescription Electronic Reporting Act (NASPER), which provides and improves patient access to quality care, and protects patients and physicians from the deleterious effects of controlled substance misuse, abuse and trafficking. ASIPP is headquartered in Paducah, KY and currently has over 5,000 members. The American Society of Interventional Pain Physicians


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):